Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 52Gastro-enteropancreatic neuroendocrine tumor 10Carcinoma, Neuroendocrine 8Small Cell Lung Carcinoma 6Adenoma, Islet Cell 6Colorectal Neoplasms 5Carcinoma, Merkel Cell 4Pancreatic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Carcinoid Tumor 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Stomach Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms, Unknown Primary 2Neoplasms 2Microsatellite Instability 2Mesothelioma 2Lung Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Brain Neoplasms 2Biliary Tract Neoplasms 2Vulvar Neoplasms 1Vipoma 1Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Parotid Neoplasms × NET × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡